Board Member
Neumora Therapeutics, Inc. (NMRA)Chairman
Neumora Therapeutics, Inc. (NMRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Neumora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NMRA alertsPaul L. Berns is recorded as Board Member and Chairman at Neumora Therapeutics, Inc. (NMRA) since January 1, 2020 and CEO at Neumora Therapeutics, Inc. (NMRA). The newest filing on record that lists Paul L. Berns as CEO and Board Member at Neumora Therapeutics, Inc. (NMRA) is dated April 17, 2026. The newest filing on record that lists Paul L. Berns as Chairman at Neumora Therapeutics, Inc. (NMRA) is dated April 25, 2024. Neumora Therapeutics, Inc. reported in an 8-K filed August 14, 2026 that Paul L. Berns was appointed Executive Chairperson of the Board of Directors, effective August 14, 2026. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Paul L. Berns was appointed Chairman of the Board, effective February 14, 2025. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Paul L. Berns was appointed Chief Executive Officer, effective February 14, 2025. The proxy statement of Neumora Therapeutics, Inc. reports total compensation of $4,562,461 for Paul L. Berns in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 4 fiscal years. Paul L. Berns has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Neumora Therapeutics, Inc. on May 27, 2026. Neumora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neumora Therapeutics, Inc. includes Joshua Pinto (CEO and Board Member), Michael Milligan (CFO), Bill Aurora (COO) and 7 others.
“Paul L. Berns, the Company's current Chief Executive Officer, will become the Company's Executive Chairperson of the Board of Directors (the "Board"), and Joshua Pinto, Ph.D., the Company's current President, will succeed Mr. Berns as the Company's Chief Executive Officer (the "Leadership Transition") effective August 14, 2026 (the "Transition Date").”
“effective February 14, 2025, Paul L. Berns, the Company's Co-Founder and Executive Chairman of its Board of Directors (the "Board"), will transition to the roles of Chief Executive Officer and Chairman of the Board”
“It is my pleasure to welcome you to the Numura Therapeutics 2026 Annual Meeting of Stockholders. I am Paul Burns, Chairman and Chief Executive Officer. As previously announced, we are holding our annual meeting virtually and have stockholders attending via the web portal.”
“2025 marked a year of important clinical progress and execution for Numura.”
2020-01-01–present
Last confirmed April 17, 2026
2020-01-01–present
Last confirmed April 25, 2024
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
CEO, Board Member, Chairman
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neumora Therapeutics, Inc. (NMRA) | Chief Executive Officer | $700,000 | $4,562,461 |
| 2024 | Neumora Therapeutics, Inc. (NMRA) | Executive Chairman | $470,000 | $8,648,393 |
| 2023 | Neumora Therapeutics, Inc. (NMRA) | Executive Chairman | $537,500 | $8,570,268 |
| 2022 | Neumora Therapeutics, Inc. (NMRA) | Executive Chairman and former Chief Executive Officer | $570,000 | $2,634,924 |
